An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A company called PlexusDx put out a report about using GHK-Cu, a peptide linked to hair growth, and how to evaluate it using biomarkers and healthcare provider guidance. In short: they’re not announcing a miracle cure. They’re outlining what evidence exists, how to measure possible effects, and why you should involve a clinician rather than self-treating based on hype. GHK-Cu is a tiny protein-like molecule (a peptide) that naturally occurs in the body and can bind copper (that’s the “Cu” part). Researchers first noticed it because it shows up in skin and wound fluid and seems to be involved in healing and tissue repair. In the hair world, some lab and small human studies have suggested GHK-Cu might help hair follicles and possibly increase hair growth or thickness. It is offered in some topical products and treatments, but it’s not the same as prescription hair drugs like finasteride or minoxidil, and it’s not a guaranteed fix. What PlexusDx appears to do in this piece is put GHK-Cu into context: they discuss which biomarkers (measurable biological indicators) could be used to track changes related to hair health, and they emphasize assessing people with a healthcare provider. The underlying studies are limited—some are lab-based (cells or tissues), some are small or observational in people—and results vary. That means any benefits seen in a lab or a handful of volunteers may not translate to clear, consistent improvements in the general population. The report recommends structured evaluation rather than relying on anecdotes or marketing claims. This matters because hair-loss products get a lot of attention and money, and people may try new peptides hoping for quick results. Knowing what measurements to use (for example, scalp photography, hair counts, or specific lab markers) and involving a clinician can prevent wasted time, money, and potential delays in getting treatments that have stronger evidence. Someone considering GHK-Cu—especially if they have sudden hair loss, scalp inflammation, or underlying health issues—should be evaluated so other causes can be ruled out and so expectations are realistic. There are important caveats. GHK-Cu is not an FDA-approved hair-loss drug, and the safety and long-term effects of topical or injected use aren’t fully established. Side effects from topical use are usually local (like irritation), but comprehensive safety data is limited. People who are pregnant, breastfeeding, or on certain medications should be cautious and talk to their clinician. Also, the presence of a biomarker change doesn’t always mean a meaningful cosmetic improvement; measurable shifts in a lab test might not match visible hair regrowth. Bottom line: GHK-Cu is an interesting peptide with some early signals for hair health, but evidence is limited; consult a healthcare provider and use objective measures if you’re testing it, rather than trusting marketing or one-off anecdotes.
Source: PlexusDx